Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252. (Q33369733)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252. |
scientific article |
Statements
1 reference
Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252. (English)
1 reference
Daniel W Visscher
1 reference
Edith A Perez
1 reference
Vera J Suman
1 reference
James N Ingle
1 reference
Kendrith M Rowland
1 reference
Muhammad Salim
1 reference
Charles L Loprinzi
1 reference
Patrick J Flynn
1 reference
James A Mailliard
1 reference
Carl G Kardinal
1 reference
James E Krook
1 reference
Abby R Thrower
1 reference
Robert B Jenkins
1 reference
1 December 2005
1 reference
1 reference
Identifiers
1 reference